title: Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency.
abstract: Immunosuppressive agents are the standard therapeutic approach for immune thrombocy-topenia (ITP). Their prolonged use may increase the risk of infectious complications, particularly when the patient is already at higher infectious risk. In this setting, the use of drugs with a mechanism of action alternative to immunosuppression, like thrombopoietin receptor agonists (TRAs), may find particular indication. We report the unique case of a patient with severe immunodeficiency and ITP, who experienced a serious infectious complication while on steroids treatment, and who was successfully treated with Romiplostim second-line. The present experience supports the effectiveness and safety of TRAs as early treatment of ITP patients with drug-induced immunodeficiency or with active infections.
authors: Department of Hematology and Oncology L. e A. Seràgnoli, St. Orsola-Malpighi Hospital, University of Bologna;
authors: Francesca
authors: F
authors: Palandri
authors: Nicola
authors: N
authors: Polverelli
authors: Francesca
authors: F
authors: Lifrieri
authors: Lucia
authors: L
authors: Catani
authors: Maria Benedetta
authors: MB
authors: Giannini
authors: Michele
authors: M
authors: Baccarani
authors: Nicola
authors: N
authors: Vianelli